Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls

Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls

Abstract Background For progressive metastatic medullary thyroid carcinoma (MTC), the available treatment options with tyrosine kinase inhibitors result in grade 3–4 adverse events in a large number of patients. Peptide Receptor Radionuclide Therapy (PRRT), which has also been suggested to be a usef...

Full description

Bibliographic Details
Main Authors: Carolien M. Beukhof, Tessa Brabander, Francien H. van Nederveen, Marie-Louise F. van Velthuysen, Yolanda B. de Rijke, Leo J. Hofland, Gaston J. H. Franssen, Lideke A. C. Fröberg, Boen L. R. Kam, W. Edward Visser, Wouter W. de Herder, Robin P. Peeters
Format: Article
Language:English
Published: BMC 2019-04-01
Series:BMC Cancer
Subjects:
Thyroid cancer, medullary
Peptide receptor radionuclide therapy
Lutetium
Receptors, somatostatin
Online Access:http://link.springer.com/article/10.1186/s12885-019-5540-5

Internet

http://link.springer.com/article/10.1186/s12885-019-5540-5

Similar Items